MET and non-small cell lung carcinoma: Of interest, a randomized trial of ficlatuzumab (a humanized antibody against HGF; Aveo) in combination with an EGFR inhibitor in NSCLC failed to show efficacy in patients with high MET expression Mok et al [88].